Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 9/20 | 0.50 |
| ▸ | MAOA | P21397 | 1/20 | 0.49 |
| ▸ | MAOB | P27338 | 1/20 | 0.49 |
| ▸ | TERT | O14746 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | PARP1 | P09874 | 1/20 | 0.43 |
| ▸ | ADK | P55263 | 1/20 | 0.42 |
| ▸ | SYK | P43405 | 1/20 | 0.41 |
| ▸ | ESR1 | P03372 | 1/20 | 0.41 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12402694 | 0.90 | MAOA (0.56) | APPMAOAMAOBTERTCYP1A2 | |
| SCHEMBL13989416 | 0.86 | CYP1A2 (0.57) | CYP1A2ALDH1A1KDM4EESR1ESR2 | |
| SCHEMBL18573206 | 0.79 | ESR1 (0.61) | CYP1A2ALDH1A1ESR1ESR2 | |
| SCHEMBL62397 | 0.79 | RAB9A (0.61) | APPMAOAMAOBCYP1A2ALDH1A1 | |
| SCHEMBL398766 | 0.79 | KDM4E (0.55) | CYP1A2ALDH1A1KDM4EESR1TDP1 | |
| SCHEMBL15224383 | 0.79 | APP (0.55) | APPMAOAMAOBTERTCYP1A2 | |
| SCHEMBL28051566 | 0.78 | CYP1A2 (0.67) | CYP1A2ALDH1A1KDM4EGAATSHR | |
| SCHEMBL10147842 | 0.77 | CYP1A2 (0.59) | CYP1A2ALDH1A1KDM4EESR1ESR2 | |
| SCHEMBL13989404 | 0.77 | CYP1A2 (0.55) | CYP1A2ALDH1A1KDM4EESR1 | |
| SCHEMBL20008616 | 0.77 | TERT (0.80) | APPTERTCYP1A2ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2640703-A1 | HETEROCYCLIC COMPOUNDS AS IMAGING PROBES OF TAU PATHOLOGY | GE Healthcare UK Limited (GB) | 2013-09-25 | — | — | EP | claimed |
| US-20130236395-A1 | HETEROCYCLIC COMPOUNDS AS IMAGING PROBES OF TAU PATHOLOGY | GE HEALTHCARE LIMITED (GB) | 2013-09-12 | — | — | US | claimed |
| WO-2012067863-A1 | HETEROCYCLIC COMPOUNDS AS IMAGING PROBES OF TAU PATHOLOGY | GE HEALTHCARE LIMITED (GB) | 2012-05-24 | — | — | WO | claimed |
| US-7118730-B2 | Quinoline derivative as diagnostic probe for disease with tau protein accumulation | BF RESEARCH INSTITUTE, INC. (JP) | 2006-10-10 | — | — | US | claimed |
| US-9040021-B2 | Heterocyclic compounds as imaging probes of tau pathology | GE HEALTHCARE LIMITED (GB) | 2015-05-26 | — | — | US | disclosed |
| EP-2640703-A1 | HETEROCYCLIC COMPOUNDS AS IMAGING PROBES OF TAU PATHOLOGY | GE Healthcare UK Limited (GB) | 2013-09-25 | — | — | EP | disclosed |
| US-20130236395-A1 | HETEROCYCLIC COMPOUNDS AS IMAGING PROBES OF TAU PATHOLOGY | GE HEALTHCARE LIMITED (GB) | 2013-09-12 | — | — | US | disclosed |
| WO-2012067863-A1 | HETEROCYCLIC COMPOUNDS AS IMAGING PROBES OF TAU PATHOLOGY | GE HEALTHCARE LIMITED (GB) | 2012-05-24 | — | — | WO | disclosed |
| US-7118730-B2 | Quinoline derivative as diagnostic probe for disease with tau protein accumulation | BF RESEARCH INSTITUTE, INC. (JP) | 2006-10-10 | — | — | US | disclosed |
| US-20050009865-A1 | Quinoline derivative as diagnostic probe for disease with tau protein accumulation | BF RESEARCH INSTITUTE, INC. (JP) | 2005-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009865-A1 | Quinoline derivative as diagnostic probe for disease with tau protein accumulation | MAPT, APP, PSEN1 | APP 2/4885MAOA 1618/4885MAOB 1111/4885 |
| US-20130236395-A1 | HETEROCYCLIC COMPOUNDS AS IMAGING PROBES OF TAU PATHOLOGY | MAPT, PSEN1, PSEN2 | APP 4/4885MAOA 57/4885MAOB 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.